The evidence for unavailability of systemic antifungals in Senegal

Diongue, Khadim; Diallo, Mamadou Alpha; Seck, Mame Cheikh; Ndiaye, Mouhamadou; Badiane, Aïda Sadikh; Ndiaye, Daouda

doi:10.1177/20499361211036594

Cited by 3 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This comparative unavailability of SAs in WA could be related to the relatively low frequency of IFIs-apart from cryptococcosis-that is in turn attributable to the weakness of the technical materials and the use of slightly sensitive biological tools of diagnosis [1,26]. Therefore, this situation requires an awareness of the health authorities to capacitate the medical biology laboratories but also to revise the curricula of the medical training for a consciousness of the practitioners.…”

Section: Discussionmentioning

confidence: 99%

“…While the current antifungal arsenal in Africa has products that permit the treatment of superficial fungal infections, many invasive fungal infections (IFIs) do not yet benefit from effective treatment due to the lack of systemic antifungal (SAs) molecules [1]. However, fungi are ubiquitous; therefore, they are a major threat to human health, causing more than a billion cutaneous infections, more than 100 million mucous infections, 10 million serious allergies, and more than a million deaths each year [2].…”

Section: Introductionmentioning

confidence: 99%

“…Given that we have already demonstrated the unavailability of SAs in Senegal in a previous article [1], this study aimed to assess the availability of SAs in other African countries, as well as to compare this availability between West Africa (WA) and North Africa (NA).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Availability of Systemic Antifungals in Africa: A Comparative Study between North Africa and West Africa

Diongue,

Miezan,

et al. 2023

AJPME

Self Cite

View full text Add to dashboard Cite

Introduction. Due to the lack of systemic antifungals (SAs), many invasive fungal infections (IFIs) do not yet benefit from effective treatment in Africa. Yet, fungi are a major threat to human health. This study aimed to assess the availability of SAs and compare this availability between West Africa (WA) and North Africa (NA). Materials and methods. The information processed was obtained during the same period between February and June 2021 in Senegal, Mauritania, and Côte d’Ivoire as well as in Morocco and Tunisia. In WA, data were received from wholesale drug suppliers and private pharmacies while in NA, the data were those available on the websites of the pharmacy and drug directorates. Results. All classes of SAs were available. However, this availability was not uniform depending on location, whether in WA or NA. Fluconazole and itraconazole were the only SA available in WA. In NA, all classes of SAs have been found, particularly in Morocco, while flucytosine was the only molecule absent in Tunisia. Conclusion. NA is ahead of WA as regards the burden of IFIs both diagnostically and in the availability of SAs. Studies on the epidemiology of IFIs in Africa, particularly in WA, are limited. The partial data available highlight that IFIs are not negligible, though these may be underestimated. Thus, a network based on the directory of African pharmacy and drug directorates must be set up and run in collaboration with the national laboratory directorates for the harmonization of procedures in order to reduce morbidity and mortality related to IFIs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Availability of Systemic Antifungals in Africa: A Comparative Study between North Africa and West Africa

Diongue,

Miezan,

et al. 2023

AJPME

Self Cite

View full text Add to dashboard Cite

show abstract

“…The need to improve diagnostic capabilities for IFIs of Azerbaijan was highlighted. In the same vein, Diongue et al 24 from Senegal pointed out that despite the low frequency of IFIs for which more than half is cryptococcosis, the risk factors for IFIs are prevalent across Senegal. However, it was reported that fluconazole is the only systemic antifungal available in the country, yet it has no activity on many fungi such as Aspergillus spp.…”

mentioning

confidence: 99%